0001503274-26-000021
SEC filingQ1 revenue grew 20.1% to $36.4M, but operating loss widened 56.9% to -$41.4M from elevated costs including shipping reclassification to COGS. Net loss narrowed 14.5% to -$17.5M with EPS improving to -$0.37, reflecting strategic adjustments amid customer diversification.
The Emission transaction secures highly controlled beads for future multi-plex products, supporting expansion into a new market segment targeting third-party original equipment manufacturers. Purchase price allocation remains preliminary as the Company gathers additional information. Separately, termination of the off-market component of the Akoya customer contract—assumed in the prior acquisition—resolved related liabilities, with no amounts due to or from the Biopharma Customer as of March 31, 2026. These moves eliminate exposures and position Quanterix for innovation in multiplex technologies.